Literature DB >> 1175169

Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.

K B Bischoff.   

Abstract

The purpose of this paper is to document the procedures needed to construct pharmacokinetic models based on physiologic, physicochemical, and pharmacologic principles. Extensive descriptions of the basic ideas are provided, along with the corresponding equations. The notions of scaling between various animal species will be described and examples will be given. The important factors determining the choice and number of compartments are based on the properties of the drug and the desired purposes of the pharmacokinetic model. The important concept of flow-limiting conditions with regard to local uptake will be described. The quantitative description of plasma and tissue binding is discussed, along with the notion of effective protein concentrations for the latter. Using these basic ideas, the fundamental mass balances describing the flow, diffusion, and reactions of the drug are presented. An example of the prediction of the pharmacokinetics of a strongly bound drug is used as an illustration of the methods, and this example also indicates the types of useful simplifications that can be made. The special, but important, case of linear binding is next derived, and an example involving the drug methotrexate will illustrate the principles involved. Finally, cytosine arabinoside will be used to indicate methods that can be used for rapidly metabolized drugs. Since existing examples are primarily utilized, this paper brings together a comprehensive collection of the several sets of physiologic data and modeling techniques that have been used for the past several years. It is hoped that this documentation will provide a useful basis for the those wishing to use this approach to pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175169

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  27 in total

1.  Mathematical models in oncology: a bird's-eye view.

Authors:  P Tautu
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978

2.  A PBPK model describing a xenobiotic with a short PK event scale.

Authors:  Xiaofeng Wang; Brian E Davies
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-09       Impact factor: 2.745

Review 3.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 4.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  A semiparametric approach to physiological flow models.

Authors:  D Verotta; L B Sheiner; W F Ebling; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

6.  An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis.

Authors:  J L Gabrielsson; T Groth
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

7.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

8.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection.

Authors:  R A Pollet; C E Glatz; D C Dyer
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

10.  Analysis of methadone disposition in the pregnant rat by means of a physiological flow model.

Authors:  J L Gabrielsson; P Johansson; U Bondesson; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1985-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.